Revive Therapeutics Ltd (OTCMKTS:RVVTF) has appointed Dr. John Fahy as a Scientifics and Clinical advisor of the company to help in the expansion and analysis of clinical data on the current FDA phase 3 clinical study. The study is evaluating the efficacy and safety of Bucillamine in mild-to-moderate coronavirus patients.
Dr. Fayh to lead a study of thiol-based drugs in SARS-CoV-2
Fahy recently authored a published study, “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibits SARS-CoV-2 cell entry.” The study demonstrated that thiol-based drugs such as Bucillamine can reduce vSARS-VoV-2 spike protein binding to its receptor, prevent coronavirus infection, and also minimize entry of the SARS-CoV-2 spike pseudotyped virus. The study findings established the vulnerability of the coronavirus to thiol-based drags and thus offer a rationale for testing thiol-based drugs as proprietary COVID-19 treatments.
Interestingly Vucillamine which is a cysteine derivative with two thiol groups has been demonstrated to be 16 times more potent as an in vivo thiol donor relative to N-acetyl-cysteine. Also for over 30 years, Bucillamine has shown a favorable safety profile as a rheumatoid arthritis treatment in South Korea and Japan. Michael Frank, Revive’s CEO stated that Fayh is a renowned thiol-based drug clinical researcher who understands the mechanisms of action of Bucillamines and its relationship with SARS-CoV-2 will be vital in evaluating the company’s FDA Phase 3 study.
Phase 3 study continuing enrolment
Recently the company gave an update on the FDA Phase 3 Study in which it demonstrated that is on course to meet enrolment targets for the Independent Data and Safety Monitoring Board. As part of the first interim data analysis, the DSMB will evaluate data from 210 randomized subjects treated and followed for 28 days.
Revive’s clinical safety team has been monitoring actively the interim data of the patients and so far no safety concerns of severe adverse events have been reported. In the event, the team noticed safety concerns they will notify the DSMB to establish any risks and give recommendations. The company is targeting the enrolment of around 1,000 patients.